skip to Main Content

BMI, Lifestyle Factors and Taxane-Induced Neuropathy in Breast Cancer Patients: The Pathways Study

Lifestyle factors may be associated with chemotherapy-induced peripheral neuropathy (CIPN). We examined associations between body mass index (BMI) and lifestyle factors with CIPN in the Pathways Study, a prospective cohort of women with invasive breast cancer. Analyses included 1237 women who received taxane treatment and provided data on neurotoxicity symptoms. Baseline interviews assessed BMI (normal: <25?kg/m 2 ; overweight: 25-29.9?kg/m 2 ; obese: ?30?kg/m 2 ), moderate-to-vigorous physical activity (MVPA) (low: <2.5; medium: 2.5-5; high: >5?hours/week) and fruit/vegetable intake (low: <35 servings/week; high: ?35 servings/week). Baseline and six-month interviews assessed antioxidant supplement use (nonuser, discontinued, continued user, initiator). CIPN was assessed at baseline, six months, and 24 months using the Functional Assessment of Cancer Therapy-Taxane Neurotoxicity (FACT-NTX); a 10% decrease was considered clinically meaningful. At baseline, 65.6% of patients in the sample were overweight or obese, 29.9% had low MVPA, 57.5% had low fruit/vegetable intake, and 9.5% reported antioxidant supplement use during treatment. In multivariable analyses, increased CIPN was more likely to occur in overweight (odds ratio [OR] = 2.37, 95% confidence interval [CI] = 1.19 to 4.88) and obese patients (OR?=?3.21, 95% CI?=?1.52 to 7.02) compared with normal weight patients at 24 months and less likely to occur in patients with high MVPA compared with those with low MVPA at six (OR?=?0.56, 95% CI?=?0.34 to 0.94) and 24 months (OR?=?0.43, 95% CI?=?0.21 to 0.87). Compared with nonusers, patients who initiated antioxidant use during treatment were more likely to report increased CIPN at six months (OR?=?3.81, 95% CI?=?1.82 to 8.04). Obesity and low MVPA were associated with CIPN in breast cancer patients who received taxane treatment.

Authors: Greenlee H; Hershman DL; Shi Z; Kwan ML; Ergas IJ; Roh JM; Kushi LH

J Natl Cancer Inst. 2017 Feb 01;109(2):1-8.

PubMed abstract

Explore all studies and publications

Back To Top